RxDoctor Payments Data

Mohamad Moughrabieh, MD

Internal Medicine · Memphis, TNNPI 1063679827

Payments from drug & device makers

$1,349in general payments, 2019–2025

Across 92 payments — averaging $14.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$682
  • Sunovion Pharmaceuticals Inc.$141
  • Merck$131
  • Lilly USA, LLC$84
  • GSK$83
  • AstraZeneca$47
  • plus $180 from 9 others

What the payments were for

  • Food & beverage$1,349100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,349 in reported general payments places this provider in the 70th percentile of 2,216 internal medicine providers in Tennessee.

See all internal medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$470,513
Medicare patients
1,193
Services billed
5,912

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban2,344$564,044
NuedextaDextromethorphan Hbr/Quinidine295$124,404
IngrezzaValbenazine Tosylate21$122,210
JanuviaSitagliptin Phosphate362$80,091
LinzessLinaclotide158$79,459
BiktarvyBictegrav/Emtricit/Tenofov Ala17$70,941
JardianceEmpagliflozin268$69,999
FarxigaDapagliflozin Propanediol221$56,703
XifaxanRifaximin67$52,758
SantylCollagenase Clostridium Hist.110$48,950
XareltoRivaroxaban195$47,637
Atorvastatin Calcium4,334$47,512
OzempicSemaglutide40$46,980
TradjentaLinagliptin256$45,669
EntrestoSacubitril/Valsartan194$43,851

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat$13$130,693560 claims
AbbVieLinzess, Creon$14$101,011211 claims
MerckJanuvia$131$80,091362 claims
AstraZenecaFarxiga, Brilinta$47$76,077311 claims
Johnson & JohnsonXarelto, Risperdal Consta$16$69,251221 claims
GSKBreo Ellipta, Trelegy Ellipta$83$61,856113 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$16$52,75867 claims
Novo NordiskOzempic$682$46,98040 claims
Lilly USA, LLCTrulicity$84$21,75220 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,216 internal medicine providers in Tennessee.

Other internal medicine in Memphis

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →